Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
Publication Type:
Journal Article
Authors:
Charlton, Michael;
Everson, Gregory T.;
Flamm, Steven L.;
Kumar, Princy;
Landis, Charles;
Brown, Robert S.;
Fried, Michael W.;
Terrault, Norah A.;
O'Leary, Jacqueline G.;
Vargas, Hugo E.;
Kuo, Alexander;
Schiff, Eugene;
Sulkowski, Mark S.;
Gilroy, Richard;
Watt, Kymberly D.;
Brown, Kimberly;
Kwo, Paul;
Pungpapong, Surakit;
Korenblat, Kevin M.;
Muir, Andrew J.;
Teperman, Lewis;
Fontana, Robert J.;
Denning, Jill;
Arterburn, Sarah;
Dvory-Sobol, Hadas;
Brandt-Sarif, Theo;
Pang, Phillip S.;
McHutchison, John G.;
Reddy, K. Rajender;
Afdhal, Nezam;
SOLAR-1 InvestigatorsSource:
Gastroenterology, Volume 149, Issue 3, p.649-659 (2015)
Keywords:
Antiviral Agents,
Benzimidazoles,
Cholestasis, Intrahepatic,
Decompensated Cirrhosis,
Disease Progression,
Drug Combinations,
Drug Therapy, Combination,
Female,
Fibrosing Cholestatic Hepatitis,
Fluorenes,
Genotype,
Hepacivirus,
Hepatitis C Virus Infection,
Hepatitis C, Chronic,
Humans,
Liver Cirrhosis,
Liver Transplantation,
Male,
Middle Aged,
Ribavirin,
Time Factors,
Treatment Outcome,
United States,
Uridine Monophosphate
